Pharma Equity Group A/S announced a private placement to issue 10% convertible term loan for the gross proceeds of DKK 9,632,073 on April 28, 2026. The loan bears interest at 10% per annum and remains without instalments until the end of the exercise period, after which the company must repay the loan including interest within 60 days, however, the company may extend the loan period by 12 months. The lender's right to convert the loans into shares in the company may be exercised for a period of 30 days commencing the first day of the 24th month after the conclusion of the convertible loan.
The company can choose to pay the loan including interest in shares. Upon conversion of the loans into new shares, the new shares will be without pre-emptive rights for the company's existing shareholders and with the same rights as the company's existing shares. The new shares will therefore be admitted to trading on Nasdaq Copenhagen.
The conversion will take place at a price corresponding to an amount of DKK 0.10 being converted into one new share in the company with a nominal value of DKK 0.10. The maximum increase in share capital as a result of conversion of the convertible loans is DKK 12,697,459.
